ONIVYDE plus carboplatin for advanced gut neuroendocrine cancer
Part of Cancer clinical trials.
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed as advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma on biopsy
- You have either not had chemotherapy before, or your last chemotherapy was given more than 6 months before your cancer came back
- There must be at least one measurable tumor spot on scans
- You are age 20 to 80, and your general health score (ECOG) is 0 to 1
- Your kidneys, liver, and blood counts must be within allowed limits
- You must have a heart rhythm test (ECG) that is normal or not clinically concerning
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether cabozantinib plus lanreotide can slow or shrink gastroenteropancreatic neuroendocrine tumors that have gotten worse despite previous treatments. If you qualify, you’ll be closely monitored for tumor response and side effects.
This study looks at how safe and effective the drug ONIVYDE (liposomal irinotecan) is when given with two other chemotherapy drugs (5-FU and leucovorin) for people with pancreatic cancer that has spread. It follows patients who are already being prescribed this treatment by their doctor.
This trial tests whether a liposomal form of the chemotherapy drug irinotecan can help people with advanced neuroendocrine tumors or cancers of the pancreas or gastrointestinal tract. It is designed for those who have not had prior systemic treatment or who have not received it yet.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) for people with advanced, aggressive neuroendocrine cancer that has not responded to at least one prior treatment. The goal is to see if this version of the drug works better or has fewer side effects.
This Phase 2 study tests a chemotherapy approach in people with metastatic grade 3 (high-grade) neuroendocrine cancer or a related rare mixed tumor. It may help shrink tumors and control disease when standard first treatments have not yet been given.
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Hear when a new GEP-NET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.